(Q44071061)

29 November 2017

title

Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment (English)

1 reference

29 November 2017

0 references

1 reference

chronic liver disease

0 references

1 reference

Toshihiko Kirishima

1

1 reference

29 November 2017

Takeshi Okanoue

2

1 reference

29 November 2017

Yukiko Daimon

3

1 reference

29 November 2017

Yoshito Itoh

4

1 reference

29 November 2017

Hideki Nakamura

5

1 reference

29 November 2017

Atsuhiro Morita

6

1 reference

29 November 2017

Tetsuya Toyama

7

1 reference

29 November 2017

Masahito Minami

8

1 reference

29 November 2017

publication date

1 August 2002

1 reference

29 November 2017

published in

Journal of Hepatology

1 reference

29 November 2017

volume

37

1 reference

29 November 2017

issue

2

1 reference

29 November 2017

page(s)

259-265

1 reference

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

Long-term therapy of chronic hepatitis B with lamivudine.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

Lamivudine resistance in hepatitis B: mechanisms and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

Clinical implications of lamivudine resistance by HBV

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

Lamivudine resistance inimmunocompetent chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

Single base pair mutation analysis by PNA directed PCR clamping

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

Facilitated detection of oncogene mutations from exfoliated tissue material by a PNA-mediated 'enriched PCR' protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

Peptide nucleic acid (PNA): its medical and biotechnical applications and promise for the future.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

Tbe complete nudeotide sequences of the cloned hepatitis B vims DNA; subtype adr and adw

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900145-9

7 January 2021

10.1016/S0168-8278(02)00145-9

Identifiers

DOI

1 reference

29 November 2017

1 reference